Novartis Zelnorm uptake
More than 70% of "top-tier" gastrointestinal specialists are prescribing the irritable bowel syndrome agent Zelnorm, Novartis Pharmaceutical CEO Thomas Ebeling tells investors April 15. "Tier one" physicians have on average 16-18 patients on tegaserod, he says. By comparison, second and third tier specialists have six to eight patients on the IBS agent, with roughly 45% and 35% of tier two and three physicians prescribing, respectively. Novartis previously described uptake for the specialist community as a whole, with 25% prescribing Zelnorm (1"The Pink Sheet" Oct. 21, 2002, p. 24)...
You may also be interested in...
The uptake of Novartis' irritable bowel syndrome therapy Zelnorm will accelerate after physicians obtain more "feedback" from early users, U.S. Commercial Operations General Manager Kurt Graves said Oct. 17 during a Novartis R&D briefing in New York City
The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine.
Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.